Evaluation of tumor marker HE4 assay on the Elecsys 2010 analyzer
Author(s) -
Jozo Ćorić,
Lejla Hasanbegović,
Aleksandar Bodulović,
Jasminka Mujić
Publication year - 2014
Publication title -
journal of health sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.112
H-Index - 3
eISSN - 2232-7576
pISSN - 1986-8049
DOI - 10.17532/jhsci.2014.148
Subject(s) - spectrum analyzer , epithelial ovarian cancer , immunoassay , medicine , ovarian cancer , biomarker , oncology , cancer , chemistry , immunology , computer science , biochemistry , telecommunications , antibody
Whey-acidic protein human epididymis protein 4 (HE4) is a new promising biomarker for epithelial ovarian cancer. The measured HE4 values may depend on the testing procedure used. The aim of this study was to evaluate the Methods : We evaluated a HE4 method on Elecsys 2010 analyzer. The method for quantitative determination of HE4 is direct, competitive chemiluminescent immunoassay. For quality control we use Elecsys PreciControl HE4 1 and 2. HE4 was measure on sera obtained from 56 women ( 20 healthy and 36 with epithelial ovarian cancer). Results: The Roche HE4 assays showed a good linearity (r=0.99) and precision (intrassayed total CV<5%). The median HE4 serum concentrations was significantly higher among EOC patients than healthy females (p<0,05). Elevated levels HE4 were found in 78 % patients with epithelial ovarian cancer. Conclusions : The presented results of the analytical evaluation methods for the determination of HE4 on the Elecsys 2010 analyzer showed an acceptable accuracy and precision.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom